The Hashemites (Arabic: الهاشميون, Al-Hāshimīyūn; also House of Hashim) are the ruling royal family of Jordan. The House was also the royal family of Syria (1920), Hejaz (1916–1925) and Iraq (1921–1958). The family belongs to the Dhawu Awn, one of the branches of the Hasanid Sharifs of Mecca – also known as Hashemites – who ruled Mecca continuously from the 10th century until its conquest by the House of Saud in 1924. Their eponymous ancestor is Hashim ibn Abd Manaf, great-grandfather of Muhammad. Traditionally, Islam has had a rich history of the veneration of relics, especially of those attributed to Muhammad. The most genuine prophetic relics are believed to be those housed in the Hirkai Serif Odasi (Chamber of the Holy Mantle) in Istanbuls Topkapı Palace. Indication of descent
In the early period, other than general usage, the Arabs also allowed the terms Sayyid and Sharif to descendants from both Hasan ibn Ali and Husayn ibn Ali. However, in the modern era, the term Sharif (Sharifah for females) has been used to denote descendants from Hasan, and the term Sayyid (Sayyidah, Syeda for females) has been used to denote descendants from Husayn.Shia Sayyid scholars wear black turbans, while non-Sayyid Shia scholars wear other colors (most commonly white). Sunni Sayyids often use the last name Shah or Hashmi. The descendants of Ali and his other wives are called Alevi sayyid; they are titled Shah, Sain, Miya Fakir or Dewan.
Also, the accelerated approval of golodirsen has paved the way for the patients to have early access to the drug, at the same time, it shrouded with controversy over a number of issues. A double-blind placebo-controlled confirmatory trial (NCT02500381) is ongoing to resolve the issues. History
Golodirsen was developed by collaborative research led by Prof. Steve Wilton and Prof. Sue Fletcher in the Perron Institute and licensed to Sarepta Therapeutics by the University of Western Australia.In the pivotal clinical trial of golodirsen, dystrophin levels increased, on average, from 0.10% of normal at baseline to 1.02% of normal after 48 weeks of treatment with the drug or longer. The change was a surrogate endpoint and the trial did not establish clinical benefit of the drug, including changes to the subjects motor function.The pharmacological assessment of golodirsen did not include special population groups, e.g., pregnant and lactating women, the elderly, and patients with concurrent disease states. As DMD predominantly affects male children and young adults, and golodirsen is indicated for the treatment of pediatric patients, but primarily not for adult women, the elderly, and patients with comorbidity, it was not evaluated on them.The US Food and Drug Administration (FDA) approved golodirsen in December 2019, under the accelerated approval pathway. The application for golodirsen was granted fast track designation, priority review designation, orphan drug designation, and a rare pediatric disease priority review voucher. References
External links
"Golodirsen". Drug Information Portal. U.S. National Library of Medicine (NLM).